Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Group Says S. Korea Drug Regulator Gives Pfizer Favorable Treatment

This article was originally published in PharmAsia News

Executive Summary

South Korean drug makers and civic groups accuse Pfizer of being "too cozy" with the country's drug regulators, citing a case in which one of its products received favorable treatment. The U.S. firm's anti-cholesterol Lipitor (atorvastatin) earlier this month received favorable treatment during price-setting decisions by the Health Insurance Review and Assessment Service, based on an economic feasibility assessment of cholesterol drugs. A Korean coalition of civic health groups said HIRA changed its pricing standards to hand Pfizer a favor worth as much as $20.7 million. A Pfizer spokeswoman said the Lipitor price cap already had been "slashed" by 20 percent in September when generics became available. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel